South East London Area Prescribing Committee
Formulary recommendation

Reference	**031**
Intervention:	**Modified release ropinirole for the treatment of Parkinson's disease** (Ropinirole is a dopamine agonist)
Date of Decision	**April 2015**
Date of Issue:	**May 2015**
Recommendation:	**Amber – treatment can be initiated in primary care on the advice of a specialist only and in line with the criteria below.**
Further Information	• Modified release ropinirole is accepted for use in South East London within its licensed indication for Parkinson's disease. • The modified release preparation may particularly be of use in patients who are already taking ropinirole immediate-release and in whom satisfactory symptomatic control has been established but it would be beneficial for them to receive the modified release version, for example, in patients with memory loss or confusion. • Treatment should be initiated in primary care **on the advice of a specialist only**. • The addition of modified release ropinirole to the formulary should also improve care for patients with Parkinson's disease who are admitted to hospital on existing modified release ropinirole therapy as they will not need to be switched to the immediate release version.
Shared Care/ Transfer of care required:	Not necessary - ropinirole is already routinely prescribed in primary care without shared care.
Cost Impact for agreed patient group	• Based on current Drug Tariff prices (April 2015) ropinirole modified release costs ~£400 more per patient per year vs. immediate release ropinirole (using 8mg dose). • However, prescribing of modified release ropinirole is already being initiated by GPs in primary care upon specialist request, therefore it is not anticipated that this will have a significant additional cost impact.
Usage Monitoring & Impact Assessment	Acute Trusts: • Monitor usage on a 6-monthly basis and report back to APC.
	CCGs: • Monitor epact data
Evidence reviewed	**References (from evidence evaluation)** 1. National Institute of Health and Clinical Excellence. Parkinson's Disease: Diagnosis and management in primary and secondary care; Clinical Guideline 35. June 2006 . Available at https://www.nice.org.uk/guidance/cg35/resources/guidance-parkinsons-disease-pdf, accessed April 2015 2. Summary Of Product Characteristics; Requip XL® accessed via www.medicines.org.uk on 8/4/15 3. Medicines and Healthcare Products Regulatory Agency. United Kingdom Public Assessment Report: Requip XL May 2008. Available at:

	http://www.mhra.gov.uk/home/groups/pl-a/documents/websiteresources/con020571.pdf accessed April 2015 4. All Wales Medicines Strategy Group; Final Appraisal Report: Ropinirole prolonged-release (Requip XL®) for the treatment of idiopathic Parkinson's disease; Advice No: 1409 – August 2009. http://www.awmsg.org/awmsgonline/app/appraisalinfo/266 accessed April 2015

NOTES:

a) Area Prescribing Committee recommendations and minutes are available publically on member CCG websites.

b) This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if new data becomes available, costs are higher than expected or new NICE guidelines or technology appraisals are issued.

c) Not to be used for commercial or marketing purposes. Strictly for use within the NHS